Deflazacort

CAS 14484-47-0 6 current records 1 historicalSmall Molecule

Who holds supplier records for Deflazacort? 6 organisations hold a current record for Deflazacort: an active US FDA Type II Drug Master File or a CEP. A further 1 organisation has only historical (inactive) DMF filings. 1 of them holds a valid EU Certificate of Suitability. Recorded organisation countries for current records: Italy (3), India (2) and China (1).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Deflazacort: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/deflazacort

Reading the evidence

  • 6 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 5 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

Current records (6)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Deflazacort. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Deflazacort sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (1)

Certificates of Suitability on the EDQM register for Deflazacort, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

HolderCountryCertificateIssuedEU GMP at holder's address
EUROAPI ITALY S.R.L. BrindisiIT
R1-CEP 2000-339 - Rev 04
Deflazacort
Dec 2021—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (1)

Organisations whose Type II DMFs for Deflazacort are no longer active. These show a past filing, not current supply.

Show all 1 historical record
  • SCHERING AG
    Inactive DMF 4922 · filed Mar 1983

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (39 listed products contain Deflazacort). The latest listed exclusivity ended 7 Jun 2026. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Deflazacort is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1201891).

Chemical identity

IUPAC name
[2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-6,9,13-trimethyl-16-oxo-5-oxa-7-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-6,14,17-trien-8-yl]-2-oxoethyl] acetate
Canonical SMILES
CC1=N[C@@]2([C@H](O1)C[C@@H]3[C@@]2(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)C=C[C@]45C)O)C)C(=O)COC(=O)C
InChIKey
FBHSPRKOSMHSIF-GRMWVWQJSA-N
Synonyms
Azacortinol, Calcort, Deflazacort, DL-458IT, Emflaza, L-5458, MDL 458, MDL-458, MDL458, Zamene, Deflazacortum, Deflazacort Oral

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Corticosteroid
Mechanism of action
Corticosteroid Hormone Receptor Agonists

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Deflazacort?

6 organisations hold an active US FDA Type II Drug Master File or a CEP for Deflazacort: CORAL DRUGS PVT LTD (India), NEWCHEM SPA (Italy), STERLING SPA (Italy), SYMBIOTEC PHARMALAB PRIVATE LTD (India), TIANJIN TIANYAO PHARMACEUTICALS CO LTD (China) and EUROAPI ITALY SRL (Italy). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Deflazacort Drug Master Files are active?

CORAL DRUGS PVT LTD (DMF 38936), NEWCHEM SPA (DMF 38357), STERLING SPA (DMF 30313), SYMBIOTEC PHARMALAB PRIVATE LTD (DMF 24691) and TIANJIN TIANYAO PHARMACEUTICALS CO LTD (DMF 35535). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Deflazacort records mean?

1 organisation has only inactive Type II DMFs for Deflazacort. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Deflazacort have a European Certificate of Suitability?

Yes. 1 organisation holds a valid CEP for Deflazacort on the EDQM register, including EUROAPI ITALY S.R.L. Brindisi (IT). A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

How do I qualify a Deflazacort supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Deflazacort?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.